

Message

From: Surekha Gangakhedkar [/O=Theranos Organization/OU=First Administrative Group/CN=Recipients/CN=Surekhag]
Sent: 8/23/2011 11:17:02 PM
To: Elizabeth Holmes [eholmes@theranos.com]
Subject: RE: Assays

Here is the updated file including all assays in the 95% list.

Surekha

From: Elizabeth Holmes
Sent: Tuesday, August 23, 2011 2:12 PM
To: Surekha Gangakhedkar
Subject: RE: Assays

Great. Please also add the other ELISAs that we've developed but are not complete to this list and send again

From: Surekha Gangakhedkar
Sent: Tuesday, August 23, 2011 1:39 PM
To: Elizabeth Holmes
Subject: RE: Assays

Hi Elizabeth,

Here is the update on the ELISA assay progress. The summary checklist tab details the stage that the assays are at and some of the issues we are trying to solve. The tabs - Development and Validation detail the plans for the experiments for the assays. Plan 1 is for Quantitative antigen assays and Plan 2 is for the Antibody ELISAs. The experiments highlighted in yellow are the Validation experiments that have to be repeated on the system.

Surekha

From: Elizabeth Holmes
Sent: Tuesday, August 23, 2011 8:42 AM
To: Surekha Gangakhedkar
Subject: Assays

Surekha –
Please send me the list of the new ELISAs which are complete and which ones are almost complete as of today. Thanks,
Elizabeth.

Elizabeth Holmes
CEO
Theranos, Inc.

Tel: 650.470.6111
Fax: 650.838.9804

=====
PRIVILEGED AND CONFIDENTIAL COMMUNICATION
IMPORTANT -- This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and

delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.

Theranos, Inc., 3200 Hillview Avenue, Palo Alto, CA, 94304

650-838-9292 www.theranos.com

=====

File Produced in Native Format